{
  "FullStudiesResponse":{
    "APIVrs":"1.01.02",
    "DataVrs":"2020:10:21 23:46:49.950",
    "Expression":"NCT04573270",
    "NStudiesAvail":355424,
    "NStudiesFound":1,
    "MinRank":1,
    "MaxRank":1,
    "NStudiesReturned":1,
    "FullStudies":[
      {
        "Rank":1,
        "Study":{
          "ProtocolSection":{
            "IdentificationModule":{
              "NCTId":"NCT04573270",
              "OrgStudyIdInfo":{
                "OrgStudyId":"Pro00043080"
              },
              "Organization":{
                "OrgFullName":"Thomas Advanced Medical LLC",
                "OrgClass":"INDUSTRY"
              },
              "BriefTitle":"Mesenchymal Stem Cells for the Treatment of COVID-19",
              "OfficialTitle":"A Pilot Phase Study Evaluating the Effects of a Single Mesenchymal Stem Cell Injection in Patients With Suspected or Confirmed COVID-19 Infection and Healthcare Providers Exposed to Coronavirus Patients"
            },
            "StatusModule":{
              "StatusVerifiedDate":"September 2020",
              "OverallStatus":"Completed",
              "ExpandedAccessInfo":{
                "HasExpandedAccess":"No"
              },
              "StartDateStruct":{
                "StartDate":"April 24, 2020",
                "StartDateType":"Actual"
              },
              "PrimaryCompletionDateStruct":{
                "PrimaryCompletionDate":"August 20, 2020",
                "PrimaryCompletionDateType":"Actual"
              },
              "CompletionDateStruct":{
                "CompletionDate":"September 1, 2020",
                "CompletionDateType":"Actual"
              },
              "StudyFirstSubmitDate":"September 23, 2020",
              "StudyFirstSubmitQCDate":"September 30, 2020",
              "StudyFirstPostDateStruct":{
                "StudyFirstPostDate":"October 5, 2020",
                "StudyFirstPostDateType":"Actual"
              },
              "LastUpdateSubmitDate":"September 30, 2020",
              "LastUpdatePostDateStruct":{
                "LastUpdatePostDate":"October 5, 2020",
                "LastUpdatePostDateType":"Actual"
              }
            },
            "SponsorCollaboratorsModule":{
              "ResponsibleParty":{
                "ResponsiblePartyType":"Sponsor"
              },
              "LeadSponsor":{
                "LeadSponsorName":"Thomas Advanced Medical LLC",
                "LeadSponsorClass":"INDUSTRY"
              },
              "CollaboratorList":{
                "Collaborator":[
                  {
                    "CollaboratorName":"HeartStem Institute",
                    "CollaboratorClass":"UNKNOWN"
                  }
                ]
              }
            },
            "OversightModule":{
              "IsFDARegulatedDrug":"Yes",
              "IsFDARegulatedDevice":"No",
              "IsUSExport":"Yes"
            },
            "DescriptionModule":{
              "BriefSummary":"This double blind, placebo controlled, multi-arm, multi-site study investigates the safety and efficacy of stem cell therapy for the treatment of patients admitted to hospital suffering complications from COVID-19 and the treatment of healthy subjects (healthcare providers) for prophylactic effect following those patients.",
              "DetailedDescription":"Recent preliminary data from Wuhan/China have claimed that intravenous injections of mesenchymal stem cells derived from human umbilical chords have resulted in complete recovery of COVID-19 infected elderly patients with respiratory failure.\n\nThis study investigates the efficacy and safety of a single umbilical cord derived stem cell intravenous injection in patients with suspected or confirmed COVID-19 infection with fever and respiratory illness.\n\nA second arm will test efficacy and safety of a single umbilical cord derived stem cell intravenous injection to healthcare providers at high exposure rates to COVID-19 infection."
            },
            "ConditionsModule":{
              "ConditionList":{
                "Condition":[
                  "Covid19",
                  "Prophylaxis"
                ]
              },
              "KeywordList":{
                "Keyword":[
                  "stem cell therapy",
                  "umbilical cord stem cells",
                  "amniotic stem cells",
                  "stem cells",
                  "MSC",
                  "Mesenchymal Stem Cell",
                  "Medicinal Signaling Cell"
                ]
              }
            },
            "DesignModule":{
              "StudyType":"Interventional",
              "PhaseList":{
                "Phase":[
                  "Phase 1"
                ]
              },
              "DesignInfo":{
                "DesignAllocation":"Randomized",
                "DesignInterventionModel":"Single Group Assignment",
                "DesignInterventionModelDescription":"This study is a randomized assignment, double-blind, placebo-controlled, multi-arm, multi-site study located at Southern California Hospitals at Culver City and Hollywood.",
                "DesignPrimaryPurpose":"Treatment",
                "DesignMaskingInfo":{
                  "DesignMasking":"Triple",
                  "DesignWhoMaskedList":{
                    "DesignWhoMasked":[
                      "Participant",
                      "Care Provider",
                      "Investigator"
                    ]
                  }
                }
              },
              "EnrollmentInfo":{
                "EnrollmentCount":"40",
                "EnrollmentType":"Actual"
              }
            },
            "ArmsInterventionsModule":{
              "ArmGroupList":{
                "ArmGroup":[
                  {
                    "ArmGroupLabel":"COVID-19 Patients Experimental",
                    "ArmGroupType":"Experimental",
                    "ArmGroupDescription":"13 COVID-19 infected subjects (Patients admitted to hospital suffering complications from COVID-19) will be randomized and equally distributed between placebo and experimental intervention.",
                    "ArmGroupInterventionList":{
                      "ArmGroupInterventionName":[
                        "Biological: PrimePro"
                      ]
                    }
                  },{
                    "ArmGroupLabel":"COVID-19 Patients Placebo",
                    "ArmGroupType":"Placebo Comparator",
                    "ArmGroupDescription":"13 COVID-19 infected subjects (Patients admitted to hospital suffering complications from COVID-19) will be randomized and equally distributed between placebo and experimental intervention.",
                    "ArmGroupInterventionList":{
                      "ArmGroupInterventionName":[
                        "Other: Placebo"
                      ]
                    }
                  },{
                    "ArmGroupLabel":"Healthcare Providers Experimental",
                    "ArmGroupType":"Experimental",
                    "ArmGroupDescription":"7 healthy subjects (healthcare providers following patients admitted to hospital suffering complications from COVID-19) will be randomized and equally distributed between placebo and experimental intervention.",
                    "ArmGroupInterventionList":{
                      "ArmGroupInterventionName":[
                        "Biological: PrimePro"
                      ]
                    }
                  },{
                    "ArmGroupLabel":"Healthcare Providers Placebo",
                    "ArmGroupType":"Placebo Comparator",
                    "ArmGroupDescription":"7 healthy subjects (healthcare providers following patients admitted to hospital suffering complications from COVID-19) will be randomized and equally distributed between placebo and experimental intervention.",
                    "ArmGroupInterventionList":{
                      "ArmGroupInterventionName":[
                        "Other: Placebo"
                      ]
                    }
                  }
                ]
              },
              "InterventionList":{
                "Intervention":[
                  {
                    "InterventionType":"Biological",
                    "InterventionName":"PrimePro",
                    "InterventionDescription":"Intravenous Injection",
                    "InterventionArmGroupLabelList":{
                      "InterventionArmGroupLabel":[
                        "COVID-19 Patients Experimental",
                        "Healthcare Providers Experimental"
                      ]
                    }
                  },{
                    "InterventionType":"Other",
                    "InterventionName":"Placebo",
                    "InterventionDescription":"Intravenous Injection",
                    "InterventionArmGroupLabelList":{
                      "InterventionArmGroupLabel":[
                        "COVID-19 Patients Placebo",
                        "Healthcare Providers Placebo"
                      ]
                    }
                  }
                ]
              }
            },
            "OutcomesModule":{
              "PrimaryOutcomeList":{
                "PrimaryOutcome":[
                  {
                    "PrimaryOutcomeMeasure":"Survival Rates",
                    "PrimaryOutcomeDescription":"Survival Rate in COVID-19 infected patients admitted to hospital for complications",
                    "PrimaryOutcomeTimeFrame":"30 Days"
                  },{
                    "PrimaryOutcomeMeasure":"Contraction Rates",
                    "PrimaryOutcomeDescription":"Contraction Rate of COVID-19 in healthy healthcare workers following patients admitted to hospital for complications due to COVID-19",
                    "PrimaryOutcomeTimeFrame":"30 Days"
                  }
                ]
              }
            },
            "EligibilityModule":{
              "EligibilityCriteria":"Inclusion Criteria:\n\nAge 18 and older\nAbility to provide informed consent\n\nExclusion Criteria:\n\nActive or recent malignancy (within last 2 years)\nInability to provide informed consent\nCurrent enrollment in any other COVID-19 treatment study",
              "HealthyVolunteers":"Accepts Healthy Volunteers",
              "Gender":"All",
              "MinimumAge":"18 Years",
              "StdAgeList":{
                "StdAge":[
                  "Adult",
                  "Older Adult"
                ]
              }
            },
            "ContactsLocationsModule":{
              "OverallOfficialList":{
                "OverallOfficial":[
                  {
                    "OverallOfficialName":"Ernst R Von Schwarz, MD, PhD",
                    "OverallOfficialAffiliation":"HeartStem Institute, Southern California Hospital at Culver City",
                    "OverallOfficialRole":"Principal Investigator"
                  }
                ]
              },
              "LocationList":{
                "Location":[
                  {
                    "LocationFacility":"Southern California Hospital at Culver City / Southern California Hospital at Hollywood",
                    "LocationCity":"Culver City",
                    "LocationState":"California",
                    "LocationZip":"92032",
                    "LocationCountry":"United States"
                  }
                ]
              }
            },
            "IPDSharingStatementModule":{
              "IPDSharing":"No",
              "IPDSharingDescription":"Data will be blinded and password protected. Research publications will be produced for medical journals. Participating Investigators will have password protected access only."
            }
          },
          "DerivedSection":{
            "MiscInfoModule":{
              "VersionHolder":"October 22, 2020"
            },
            "ConditionBrowseModule":{
              "ConditionBrowseLeafList":{
                "ConditionBrowseLeaf":[
                  {
                    "ConditionBrowseLeafId":"M8866",
                    "ConditionBrowseLeafName":"Infection",
                    "ConditionBrowseLeafRelevance":"low"
                  },{
                    "ConditionBrowseLeafId":"M19074",
                    "ConditionBrowseLeafName":"Coronavirus Infections",
                    "ConditionBrowseLeafRelevance":"low"
                  },{
                    "ConditionBrowseLeafId":"M4951",
                    "ConditionBrowseLeafName":"Communicable Diseases",
                    "ConditionBrowseLeafRelevance":"low"
                  }
                ]
              },
              "ConditionBrowseBranchList":{
                "ConditionBrowseBranch":[
                  {
                    "ConditionBrowseBranchAbbrev":"BC01",
                    "ConditionBrowseBranchName":"Bacterial and Fungal Diseases"
                  },{
                    "ConditionBrowseBranchAbbrev":"All",
                    "ConditionBrowseBranchName":"All Conditions"
                  },{
                    "ConditionBrowseBranchAbbrev":"BC02",
                    "ConditionBrowseBranchName":"Viral Diseases"
                  }
                ]
              }
            }
          }
        }
      }
    ]
  }
}
